Abaloparatide
Brand name: Tymlos
Rank #208 of 500 drugs by total cost
$68.4M
Total Cost
24,417
Total Claims
$68.4M
Total Cost
838
Prescribers
$2,800
Cost per Claim
1,441
Beneficiaries
25,938
30-Day Fills
$82K
Avg Cost/Provider
29
Avg Claims/Provider
About Abaloparatide
Abaloparatide (sold as Tymlos) was prescribed 24,417 times by 838 Medicare Part D providers in 2023, costing the program $68.4M. At $2,800 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 205 | Buprenorphine Hcl (Buprenorphine Hcl) | $69.7M | 205,349 |
| 206 | Prednisolone Acetate (Prednisolone Acetate) | $68.8M | 1,486,663 |
| 207 | Tenofovir Alafenamide (Vemlidy) | $68.7M | 44,509 |
| 208 | Abaloparatide (Tymlos) | $68.4M | 24,417 |
| 209 | Treprostinil Diolamine (Orenitram Er) | $68.2M | 5,964 |
| 210 | Esomeprazole Magnesium (Esomeprazole Magnesium) | $66.3M | 964,193 |
| 211 | Dabigatran Etexilate Mesylate (Dabigatran Etexilate) | $66.0M | 220,652 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology